Clinical trials: ACTH, open to volunteers
Cushing Syndrome
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
- Trial name
- NCT03708900
- Testing
- LCI699
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 12 people
- Sponsor
- RECORDATI GROUP
Type 2 Diabetes, Cortisol Excess
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol.
- Trial name
- CAPTAIN-T2D (NCT07296484)
- Testing
- clofutriben
- Where
- 61 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Sparrow Pharmaceuticals
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.
Mental Health Wellness 1, Preterm Birth
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth.
- Trial name
- MLI (NCT05012072)
- Testing
- The Mastery Lifestyle Intervention
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Microgen LLC
Hypertension, Hypercortisolemia
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically…
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Trial name
- LINC CARE (NCT07247162)
- Testing
- Osilodrostat
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- RECORDATI GROUP